Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, and CAR-T cell therapy research.
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
The Phase 2 Stargaze Trial of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Combination with Ruxolitinib for Steroid-Refractory Gastrointestinal (GI) Acute Graft-Versus-Host Disease (aGvHD): Comparisons with a MAGIC Control Cohort
Grade I acute graft-vs-host disease: Treat or not?
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
A Day 14 Endpoint for Acute GVHD Clinical Trials
CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
Safety and Efficacy of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease (aGvHD) in Combination with Best Available Therapy: Results from a Multicenter, Randomized, Single-Blind, Proof-of-Concept, Phase 2 Stargaze Trial
The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
The utility of biomarkers in acute GVHD prognostication
Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study
A Day 14 Endpoint for Acute Gvhd Clinical Trials
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial
Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review
Effective treatment of low-risk acute GVHD with itacitinib monotherapy
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study
Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy
National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease